查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1833549

2032 年奈米粒子藥物傳輸市場預測：按類型、材料、給藥途徑、應用、最終用戶和地區進行的全球分析

Nanoparticles for Drug Delivery Market Forecasts to 2032 - Global Analysis By Type, Material, Route of Administration, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球藥物輸送奈米粒子市場預計在 2025 年達到 1.057 億美元，到 2032 年將達到 1.801 億美元，預測期內的複合年成長率為 7.9%。

藥物遞送奈米顆粒是一種超小型載體，旨在將治療藥物直接輸送至目標細胞和組織。這些顆粒可增強藥物的溶解度、穩定性和生物有效性，同時最大限度地減少副作用。奈米顆粒可由脂質、聚合物、金屬和蛋白質製成，用於治療癌症、感染疾病和慢性疾病。奈米顆粒可實現控釋、穿透生物屏障和精準標靶化。其尺寸和表面特性可進行客製化，以最佳化與生物系統的相互作用，從而實現有效治療。

根據美國國立衛生研究院介紹，奈米粒子可以跨越生物屏障，實現標靶藥物輸送，提高生物有效性，並最大限度地減少治療癌症和慢性疾病的副作用。

患有慢性病和癌症的人數不斷增加

心血管疾病、糖尿病，尤其是癌症等慢性疾病的日益流行，推動了對奈米顆粒藥物遞送系統的需求。這些平台具有更高的生物有效性、更強的標靶性並減少副作用，使其成為長期疾病管理的理想選擇。隨著全球癌症患者數量的快速成長，奈米顆粒擴大應用於化療和標靶治療。這種醫療需求正在推動創新和應用，使奈米顆粒成為推進腫瘤、代謝和神經系統疾病現代治療方法的關鍵推動因素。

奈米產品的監管複雜性

嚴格的法律規範是奈米顆粒藥物遞送市場發展的一大限制因素。由於FDA和EMA等機構要求進行複雜的安全性、毒性和有效性評估，奈米藥物通常需要較長的核准時間。缺乏全球統一的指導方針進一步加劇了全球商業化的複雜性。這些挑戰增加了研發成本，延遲了產品上市，並阻礙了中小企業進入市場。因此，儘管各治療領域對創新奈米顆粒遞送平台的臨床需求強勁，但監管的複雜性阻礙了其快速推廣。

奈米顆粒疫苗和基因治療

奈米顆粒疫苗和基因療法的進展為該市場帶來了巨大的機會。奈米載體能夠增強遺傳物質的穩定性、標靶遞送和細胞攝取，從而顯著改善治療效果。它們在針對COVID-19的mRNA疫苗中的應用證明了脂質奈米顆粒的潛力，為其在感染疾病和罕見遺傳疾病中的廣泛應用鋪平了道路。個人化醫療和先進生技藥品領域不斷成長的投資進一步拓展了這些機遇，使奈米顆粒成為具有臨床和商業性前景的下一代療法的關鍵工具。

與替代技術的競爭

來自替代藥物遞送技術的競爭對市場擴張構成了威脅。單株抗體、病毒載體和先進聚合物療法等平台也提供標靶遞送，且療效已得到驗證。這些成熟的治療方法具有更清晰的監管途徑和臨床醫生熟悉度的優點。如果奈米顆粒未能展現出卓越的安全性、成本效益和擴充性，則有可能失去市場佔有率。因此，競爭平台的存在對市場成長構成了挑戰，迫使奈米顆粒創新者不斷透過創新和治療性能實現差異化。

COVID-19的影響：

COVID-19疫情顯著加速了奈米顆粒藥物遞送技術的普及，尤其是mRNA疫苗中的脂質奈米顆粒。這項全球性的成功案例凸顯了奈米載體在快速疫苗研發中的擴充性和有效性。研發資金的增加和政府支持的增加推動了奈米載體在免疫學、腫瘤學和感染疾病的更廣泛應用。儘管初期供應鏈中斷阻礙了臨床試驗，但自疫情爆發以來，對奈米醫學的投資激增。整體而言，COVID-19疫情已將奈米顆粒定位為現代醫療保健的重要工具，激發了信任、創新以及藥物遞送平台未來產品線的拓展。

脂質體市場預計將成為預測期內最大的市場

脂質體領域預計將在預測期內佔據市場主導地位，因為它具有成熟的安全性、生物相容性以及包封親水性和疏水性藥物的能力。脂質體廣泛應用於癌症治療、抗真菌治療、疫苗等領域，因為它們能夠改善標靶遞送、降低全身毒性並提高藥物溶解度。廣泛的臨床應用和FDA核准鞏固了脂質體製劑的市場地位。像Doxil）這樣的脂質體製劑的成功凸顯了其治療相關性，並確保了其在奈米顆粒藥物遞送領域的持續主導地位。

預計預測期內聚合物基細分市場將以最高複合年成長率成長

受可生物分解聚合物的進步及其在藥物傳輸領域的多功能性推動，聚合物基奈米顆粒市場預計將以最高的複合年成長率成長。這些載體可實現控釋、延長循環時間和精準靶向，使其在癌症、基因治療和神經系統疾病領域中發揮重要作用。聚合物化學領域的快速創新正在支持更安全、更有效的製劑。在不斷增加的研發投入以及製藥公司和研究機構之間合作的推動下，聚合物基奈米顆粒正迅速發展成為奈米醫學領域的前沿領域。

佔比最大的地區：

由於醫療保健投資的增加、癌症盛行率的上升以及製藥製造地的擴張，預計亞太地區將在預測期內佔據最大的市場佔有率。中國、印度和日本等國家正大力投資奈米技術研究和臨床應用。積極的政府措施、經濟高效的生產能力以及對先進療法日益成長的需求，進一步推動了奈米技術的應用。此外，學術機構和製藥公司之間的合作正在加速臨床試驗，使亞太地區成為奈米顆粒藥物傳輸應用的領先地區。

複合年成長率最高的地區：

由於強大的研發能力、先進的醫療基礎設施以及創新治療方法的早期應用，北美預計將在預測期內實現最高的複合年成長率。美國憑藉大量經FDA核准的基於奈米顆粒的藥物和疫苗，在生技公司和政府機構的大量投資支持下，處於領先地位。優惠的報銷框架、日益成長的慢性病盛行率以及強大的臨床試驗管道進一步推動了這一成長。北美在奈米醫學創新領域的領導地位鞏固了其作為成長最快的區域市場的地位。

免費客製化服務：

此報告的訂閱者可以選擇以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球藥物傳輸奈米顆粒市場（按類型）

  • 脂質體
  • 囊泡
  • 膠束
  • 固體脂質奈米粒
  • 奈米乳液
  • 聚合物奈米粒子

6. 全球藥物傳輸奈米顆粒市場（依材料）

  • 脂質基
  • 聚合物基
  • 金屬
  • 量子點
  • 樹狀聚合物
  • 碳基

7. 全球藥物傳輸奈米顆粒市場（依給藥途徑）

  • 口服
  • 靜脈
  • 外用
  • 肺
  • 鼻腔
  • 眼科
  • 經皮

8. 全球藥物傳輸奈米顆粒市場（依應用）

  • 癌症治療
  • 心血管疾病
  • 神經系統疾病
  • 感染疾病
  • 疫苗

9. 全球藥物傳輸奈米顆粒市場（依最終用戶）

  • 醫院
  • 製藥公司
  • 研究辦公室
  • 生技公司

10. 全球藥物傳輸奈米顆粒市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第 12 章：公司概況

  • Merck & Co.
  • Pfizer
  • Johnson & Johnson
  • Novartis
  • Roche
  • AbbVie
  • Sanofi
  • Amgen
  • Celgene
  • Gilead Sciences
  • GlaxoSmithKline
  • Bristol-Myers Squibb
  • Biogen
  • Eli Lilly
  • Regeneron Pharmaceuticals
  • Medtronic
  • MedImmune
Product Code: SMRC31382

According to Stratistics MRC, the Global Nanoparticles for Drug Delivery Market is accounted for $105.7 million in 2025 and is expected to reach $180.1 million by 2032 growing at a CAGR of 7.9% during the forecast period. Nanoparticles for drug delivery are ultra-small carriers designed to transport therapeutic agents directly to targeted cells or tissues. These particles enhance drug solubility, stability, and bioavailability while minimizing side effects. They can be engineered from lipids, polymers, metals, or proteins and are used in treating cancer, infections, and chronic diseases. Nanoparticles enable controlled release, crossing biological barriers, and precision targeting. Their size and surface properties are tailored to optimize interaction with biological systems for effective treatment.

According to NIH, nanoparticles enable targeted drug delivery by crossing biological barriers, improving bioavailability, and minimizing side effects in cancer and chronic disease therapies.

Market Dynamics:

Driver:

Rising chronic and cancer cases

The growing prevalence of chronic diseases, including cardiovascular disorders, diabetes, and especially cancer, is fueling demand for nanoparticle-based drug delivery systems. These platforms improve bioavailability, target precision, and reduce side effects, making them ideal for managing long-term illnesses. With cancer cases surging globally, nanoparticles are increasingly deployed in chemotherapy and targeted treatments. This medical necessity drives innovation and adoption, positioning nanoparticles as a critical enabler in advancing modern therapeutics across oncology, metabolic diseases, and neurological conditions.

Restraint:

Regulatory complexities for nano products

Stringent regulatory frameworks act as a major restraint for the nanoparticle drug delivery market. Nanomedicines often face lengthy approval timelines due to complex safety, toxicity, and efficacy evaluations required by agencies like the FDA and EMA. The absence of universally harmonized guidelines further complicates global commercialization. These challenges increase R&D costs and delay product launches, deterring smaller companies from market entry. Consequently, regulatory complexities hinder rapid adoption, despite strong clinical demand for innovative nanoparticle-based delivery platforms across therapeutic segments.

Opportunity:

Nanoparticle vaccines and gene therapy

Advancements in nanoparticle-enabled vaccines and gene therapy present immense opportunities for this market. Nanocarriers enhance stability, targeted delivery, and cellular uptake of genetic material, significantly improving treatment outcomes. Their use in mRNA COVID-19 vaccines showcased the potential of lipid nanoparticles, setting a precedent for broader applications in infectious diseases and rare genetic disorders. Growing investment in personalized medicine and advanced biologics further expands these opportunities, positioning nanoparticles as pivotal tools in next-generation therapies with high clinical and commercial promise.

Threat:

Competition from alternative technologies

Competition from alternative drug delivery technologies poses a threat to market expansion. Platforms like monoclonal antibodies, viral vectors, and advanced polymer therapeutics are also achieving targeted delivery with proven efficacy. These established modalities often benefit from clearer regulatory pathways and clinician familiarity. If nanoparticles fail to demonstrate superior safety, cost-effectiveness, and scalability, they risk losing adoption share. Consequently, the presence of competing platforms challenges market growth, compelling nanoparticle innovators to continuously differentiate through innovation and therapeutic performance.

Covid-19 Impact:

The COVID-19 pandemic significantly accelerated nanoparticle drug delivery adoption, especially through lipid nanoparticles in mRNA vaccines. This global success story highlighted the scalability and efficacy of nanocarriers in rapid vaccine development. Increased R&D funding and government support propelled broader applications in immunology, oncology, and infectious diseases. While early supply chain disruptions hampered clinical trials, post-pandemic investments in nanomedicine surged. Overall, COVID-19 positioned nanoparticles as indispensable tools in modern healthcare, catalyzing trust, innovation, and future pipeline expansion for drug delivery platforms.

The liposomes segment is expected to be the largest during the forecast period

The liposomes segment is projected to dominate the market during the forecast period, owing to their established safety profile, biocompatibility, and ability to encapsulate both hydrophilic and hydrophobic drugs. Liposomes improve targeted delivery, reduce systemic toxicity, and enhance drug solubility, making them widely used in cancer therapy, antifungal treatments, and vaccines. Strong clinical adoption and FDA approvals reinforce their market position. The success of liposomal formulations like Doxil highlights their therapeutic relevance, ensuring continued dominance within nanoparticle-based drug delivery.

The polymer-based segment is expected to have the highest CAGR during the forecast period

The polymer-based nanoparticles segment is forecasted to witness the highest CAGR, impelled by advancements in biodegradable polymers and their versatility in drug delivery. These carriers enable controlled release, prolonged circulation time, and precise targeting, making them valuable in cancer, gene therapy, and neurological disorders. Rapid innovation in polymer chemistry supports safer and more effective formulations. Increasing R&D investments and collaborations between pharmaceutical firms and research institutions are fueling growth, positioning polymer-based nanoparticles as a rapidly expanding frontier in nanomedicine.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, driven by rising healthcare investments, growing cancer prevalence, and expansion of pharmaceutical manufacturing hubs. Countries such as China, India, and Japan are investing heavily in nanotechnology research and clinical applications. Favorable government initiatives, cost-effective production capabilities, and rising demand for advanced therapies further boost adoption. Additionally, collaborations between academic institutions and pharmaceutical companies accelerate clinical trials, making Asia Pacific a leading region in nanoparticle drug delivery adoption.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR attributed to strong R&D capabilities, advanced healthcare infrastructure, and early adoption of innovative therapies. The U.S. is at the forefront with numerous FDA-approved nanoparticle-based drugs and vaccines, supported by significant investments from biotech firms and government agencies. Favorable reimbursement frameworks, rising incidence of chronic diseases, and robust clinical trial pipelines further accelerate growth. North America's leadership in nanomedicine innovation ensures its position as the fastest-growing regional market.

Key players in the market

Some of the key players in Nanoparticles for Drug Delivery Market include Merck & Co., Pfizer, Johnson & Johnson, Novartis, Roche, AbbVie, Sanofi, Amgen, Celgene, Gilead Sciences, GlaxoSmithKline, Bristol-Myers Squibb, Biogen, Eli Lilly, Regeneron Pharmaceuticals, Medtronic, and MedImmune.

Key Developments:

In August 2025, Merck & Co. launched a lipid nanoparticle platform for oncology mRNA delivery, optimizing tumor targeting while minimizing systemic toxicity. This innovation advances precision cancer therapeutics, improving safety and treatment outcomes.

In July 2025, Pfizer introduced a polymeric nanoparticle intranasal vaccine formulation, designed to strengthen mucosal immunity. By simplifying administration and logistics, it supports large-scale immunization programs with improved efficacy and patient accessibility.

In June 2025, Johnson & Johnson unveiled a dual-layer nanoparticle system for autoimmune therapies, enabling sequential release of immunomodulators. This controlled delivery approach enhances therapeutic efficacy, reduces side effects, and supports long-term immune regulation.

Types Covered:

  • Liposomes
  • Niosomes
  • Micelles
  • Solid Lipid Nanoparticles
  • Nanoemulsions
  • Polymeric Nanoparticles

Materials Covered:

  • Lipid-Based
  • Polymer-Based
  • Metallic
  • Quantum Dots
  • Dendrimers
  • Carbon-Based

Route of Administrations Covered:

  • Oral
  • Intravenous
  • Topical
  • Pulmonary
  • Nasal
  • Ocular
  • Transdermal

Applications Covered:

  • Cancer Therapy
  • Cardiovascular Diseases
  • Neurological Disorders
  • Infectious Diseases
  • Vaccines

End Users Covered:

  • Hospitals
  • Pharmaceutical Companies
  • Research Laboratories
  • Biotechnology Firms

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Nanoparticles for Drug Delivery Market, By Type

  • 5.1 Introduction
  • 5.2 Liposomes
  • 5.3 Niosomes
  • 5.4 Micelles
  • 5.5 Solid Lipid Nanoparticles
  • 5.6 Nanoemulsions
  • 5.7 Polymeric Nanoparticles

6 Global Nanoparticles for Drug Delivery Market, By Material

  • 6.1 Introduction
  • 6.2 Lipid-Based
  • 6.3 Polymer-Based
  • 6.4 Metallic
  • 6.5 Quantum Dots
  • 6.6 Dendrimers
  • 6.7 Carbon-Based

7 Global Nanoparticles for Drug Delivery Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Intravenous
  • 7.4 Topical
  • 7.5 Pulmonary
  • 7.6 Nasal
  • 7.7 Ocular
  • 7.8 Transdermal

8 Global Nanoparticles for Drug Delivery Market, By Application

  • 8.1 Introduction
  • 8.2 Cancer Therapy
  • 8.3 Cardiovascular Diseases
  • 8.4 Neurological Disorders
  • 8.5 Infectious Diseases
  • 8.6 Vaccines

9 Global Nanoparticles for Drug Delivery Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Pharmaceutical Companies
  • 9.4 Research Laboratories
  • 9.5 Biotechnology Firms

10 Global Nanoparticles for Drug Delivery Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Merck & Co.
  • 12.2 Pfizer
  • 12.3 Johnson & Johnson
  • 12.4 Novartis
  • 12.5 Roche
  • 12.6 AbbVie
  • 12.7 Sanofi
  • 12.8 Amgen
  • 12.9 Celgene
  • 12.10 Gilead Sciences
  • 12.11 GlaxoSmithKline
  • 12.12 Bristol-Myers Squibb
  • 12.13 Biogen
  • 12.14 Eli Lilly
  • 12.15 Regeneron Pharmaceuticals
  • 12.16 Medtronic
  • 12.17 MedImmune

List of Tables

  • Table 1 Global Nanoparticles for Drug Delivery Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Nanoparticles for Drug Delivery Market Outlook, By Type (2024-2032) ($MN)
  • Table 3 Global Nanoparticles for Drug Delivery Market Outlook, By Liposomes (2024-2032) ($MN)
  • Table 4 Global Nanoparticles for Drug Delivery Market Outlook, By Niosomes (2024-2032) ($MN)
  • Table 5 Global Nanoparticles for Drug Delivery Market Outlook, By Micelles (2024-2032) ($MN)
  • Table 6 Global Nanoparticles for Drug Delivery Market Outlook, By Solid Lipid Nanoparticles (2024-2032) ($MN)
  • Table 7 Global Nanoparticles for Drug Delivery Market Outlook, By Nanoemulsions (2024-2032) ($MN)
  • Table 8 Global Nanoparticles for Drug Delivery Market Outlook, By Polymeric Nanoparticles (2024-2032) ($MN)
  • Table 9 Global Nanoparticles for Drug Delivery Market Outlook, By Material (2024-2032) ($MN)
  • Table 10 Global Nanoparticles for Drug Delivery Market Outlook, By Lipid-Based (2024-2032) ($MN)
  • Table 11 Global Nanoparticles for Drug Delivery Market Outlook, By Polymer-Based (2024-2032) ($MN)
  • Table 12 Global Nanoparticles for Drug Delivery Market Outlook, By Metallic (2024-2032) ($MN)
  • Table 13 Global Nanoparticles for Drug Delivery Market Outlook, By Quantum Dots (2024-2032) ($MN)
  • Table 14 Global Nanoparticles for Drug Delivery Market Outlook, By Dendrimers (2024-2032) ($MN)
  • Table 15 Global Nanoparticles for Drug Delivery Market Outlook, By Carbon-Based (2024-2032) ($MN)
  • Table 16 Global Nanoparticles for Drug Delivery Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 17 Global Nanoparticles for Drug Delivery Market Outlook, By Oral (2024-2032) ($MN)
  • Table 18 Global Nanoparticles for Drug Delivery Market Outlook, By Intravenous (2024-2032) ($MN)
  • Table 19 Global Nanoparticles for Drug Delivery Market Outlook, By Topical (2024-2032) ($MN)
  • Table 20 Global Nanoparticles for Drug Delivery Market Outlook, By Pulmonary (2024-2032) ($MN)
  • Table 21 Global Nanoparticles for Drug Delivery Market Outlook, By Nasal (2024-2032) ($MN)
  • Table 22 Global Nanoparticles for Drug Delivery Market Outlook, By Ocular (2024-2032) ($MN)
  • Table 23 Global Nanoparticles for Drug Delivery Market Outlook, By Transdermal (2024-2032) ($MN)
  • Table 24 Global Nanoparticles for Drug Delivery Market Outlook, By Application (2024-2032) ($MN)
  • Table 25 Global Nanoparticles for Drug Delivery Market Outlook, By Cancer Therapy (2024-2032) ($MN)
  • Table 26 Global Nanoparticles for Drug Delivery Market Outlook, By Cardiovascular Diseases (2024-2032) ($MN)
  • Table 27 Global Nanoparticles for Drug Delivery Market Outlook, By Neurological Disorders (2024-2032) ($MN)
  • Table 28 Global Nanoparticles for Drug Delivery Market Outlook, By Infectious Diseases (2024-2032) ($MN)
  • Table 29 Global Nanoparticles for Drug Delivery Market Outlook, By Vaccines (2024-2032) ($MN)
  • Table 30 Global Nanoparticles for Drug Delivery Market Outlook, By End User (2024-2032) ($MN)
  • Table 31 Global Nanoparticles for Drug Delivery Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 32 Global Nanoparticles for Drug Delivery Market Outlook, By Pharmaceutical Companies (2024-2032) ($MN)
  • Table 33 Global Nanoparticles for Drug Delivery Market Outlook, By Research Laboratories (2024-2032) ($MN)
  • Table 34 Global Nanoparticles for Drug Delivery Market Outlook, By Biotechnology Firms (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.